This site is intended for Healthcare professionals only.

American Pain Society Offers Guidance on Medical Marijuana for Pain


American Pain Society Offers Guidance on Medical Marijuana for Pain

Marijuana often is used to self-treat chronic pain and, with 24 states legalizing medical use of the herb, the American Pain Society published guidance in The Journal of Pain for physicians caring for patients who use cannabis. The paper also identified opportunities for future research required to better understand the health effects of cannabinoids.

The article is a consensus report with a balanced analysis from experts with diverse opinions about the value of cannabis as a pain treatment. The authors range from legalization advocates to opponents of using cannabis, even for medical purposes.

“We looked at the evidence that is available on the use of clinical cannabis and extrapolated to some degree on management strategies from our experiences with the prescribing of controlled substances,” said lead author Seddon R. Savage, MD, medical director, Silver Hill Hospital Chronic Pain and Recovery Center, in an interview with Medscape Medical News at the recent American Pain Society annual meeting.

The article reviews clinical, research, and policy issues related to herbal cannabis to counsel clinicians in advising and caring for patients who use it, while recognizing there is a broad range of opinions among pain clinicians and researchers regarding the use of herbal cannabis. However, the authors note that many pain clinicians and researchers agree that cannabinoids are clinically promising chemical compounds, and there is a critical need for robust research on herbal cannabis to identify targets for medical development.

Clinical practice recommendations include the following:

  • Know the federal and state laws governing use of medical cannabis.
  • Be clear with patients about goals for therapeutic cannabis.
  • Counsel patients about routes of administration and potential benefits and risks, based on scientific evidence and individual symptoms, conditions, and comorbidities.
  • Advise patients on cannabis strains, cannabinoid medications, or extracts, explaining limitations because of lack of herbal/substance uniformity and regulatory oversight.
  • Monitor patients the same as for treatment with opioids or other controlled substances.
  • Patient follow-up should assess progress toward achieving treatment goals, incidence of side effects, and evidence of psychobehavioral changes.

The authors strongly advocate that a robust research agenda is needed to fully realize the clinical potential of cannabinoid therapies. They recommend

  • increasing federal funding for pain-related cannabis research
  • broadening pain conditions being studied to include cannabis for non-neuropathic pain
  • easing regulatory restrictions that impede approvals of cannabis and cannabinoid research
  • improving access to high-quality plant cannabis for research studies
  • encouraging states to collect individual and population level data on patients receiving medical cannabis.

The authors concluded that research on the cultivation of cannabis also is needed. Expanded medical use will require high-quality medicinal grade cannabis with strict quality control and known constituents.

You can read the full article by clicking on the following link :

Seddon R. Savage, Alfonso Romero-Sandoval, Michael Schatman, Mark Wallace, Gilbert Fanciullo, Bill McCarberg, Mark Ware. Cannabis in Pain Treatment: Clinical and Research Considerations. The Journal of Pain, 2016; 17 (6): 654 DOI: 10.1016/j.jpain.2016.02.007

The following two tabs change content below.
supriya kashyap

supriya kashyap

Supriya Kashyap Joined Medical Dialogue as Reporter in 2015 . she covers all the medical specialty news in different medical categories. She also covers the Medical guidelines, Medical Journals, rare medical surgeries as well as all the updates in medical filed. She is a graduate from Delhi University. She can be contacted at supriya.kashyap@medicaldialogues.in Contact no. 011-43720751
Source: self

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted